-
Proposed clinical management of pregnancies after combined screening for preeclampsia at 35-37 weeks' gestation.
Panaitescu AM, Wright D, Militello A, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017:50:383-387. pdf -
Proposed clinical management of pregnancies after combined screening for preeclampsia at 19-24 weeks' gestation.
Litwinska M, Wright D, Efeturk T, Ceccacci I, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:367-372. pdf -
Repeat measurements of uterine artery pulsatility index, mean arterial pressure and serum placental growth factor at 12, 22 and 32 weeks in the prediction of preeclampsia.
Andrietti S, Carlucci S, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:751-755. pdf -
Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation.
O'Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, Wright A, Akolekar R, Cicero S, Janga D, Jani J, Molina FS, de Paco Matallana C, Papantoniou N, Persico N, Plasencia W, Singh M, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:751-755. pdf -
Comparison of screening for preeclampsia at 31-34 weeks' gestation by the sFLT to PLGF ratio and a method combining maternal factors with sFLT-1 and PLGF.
Tan MY, Wright D, Koutoulas L, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:201-208. -
Placental growth factor in prediction of stillbirths at 11-13 weeks.
Akolekar R, Machuca M, Mendes M, Paschos V, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:618-623. pdf -
Prediction of stillbirth by placental growth factor at 19-24 weeks' gestation.
Aupont JE, Akolekar R, Illian A, Neonakis S, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:631-635. pdf -
Screening for pre-eclampsia using sFlt-1/PlGF ratio cut-off of 38 at 30-37 weeks' gestation.
Dragan I, Georgiou T, Prodan N, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:73-77. pdf -
Development of preeclampsia within four weeks of sFLT to PLGF ratio >38: Comparison of performance at 31-34 versus 35-37 weeks' gestation.
Dragan I, Wright D, Fiolna M, Leipold G, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:209-12. pdf -
Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF.
Tan MY, Wright D, Koutoulas L, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:201-8. pdf -
Proposed clinical management of pregnancies after combined screening for pre-eclampsia at 30-34 weeks' gestation.
Wright D, Dragan I, Syngelaki A, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:194-200. pdf -
Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE)
O'Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC.
BMJ Open 2016;6:e011801. pdf -
Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation.
Andrietti S, Silva M, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:72-9. pdf -
Prediction of stillbirth from placental growth factor at 19-24 weeks.
Aupont JE, Akolekar R, Illian A, Neonakis S, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:631-5. pdf -
Prediction of stillbirth from placental growth factor at 11-13 weeks.
Akolekar R, Machuca M, Mendes M, Paschos V, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:618-23. pdf -
Prediction of stillbirth from biochemical and biophysical markers at 11-13 weeks.
Mastrodima S, Akolekar R, Yerlikaya G, Tzelepis T, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:613-7. pdf -
Contingent screening for preterm pre-eclampsia.
Wright D, Gallo DM, Gil Pugliese S, Casanova C, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:554-9. pdf -
Maternal serum placental growth factor at 12, 22, 32 and 36 weeks' gestation in screening for pre-eclampsia.
Tsiakkas A, Cazacu R, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:472-7. pdf -
Prediction of large-for-gestational-age neonates: screening by maternal factors and biomarkers in the three trimesters of pregnancy.
Frick AP, Syngelaki A, Zheng M, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:332-9. pdf -
Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
Khalil A, Maiz N, Garcia-Mandujano R, Penco JM, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:324-31. pdf